Completed NA INTERVENTIONAL 1-arm NCT05365386

Efficacy and Safety of Tixel Treatment on Facial and/or Scalp Actinic Keratoses.

Evaluation of the Efficacy and Safety of a Thermal Fractional Skin Treatment System (TIXEL®) for the Treatment of Facial and / or Scalp Actinic Keratoses.

Sponsor: Novoxel Ltd.

Conditions Actinic Keratoses

Interventions Tixel C

Updated 6 times since 2022 Last updated: Nov 26, 2024 Started: May 17, 2022 Primary completion: Sep 12, 2023 Completion: Sep 12, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Actinic Keratoses and is currently completed. Novoxel Ltd. leads this study, which shows 6 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Jan 2025 — Sep 2025 [monthly]

Completed NA
Sep 2024 — Jan 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Feb 2024 — Jul 2024 [monthly]

Completed NA

Status: Recruiting → Completed

▶ Show 1 earlier version

Jun 2022 — Feb 2024 [monthly]

Recruiting NA

First recorded

May 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novoxel Ltd.

Data source: Novoxel Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Petah Tikva, Israel